Get the Stockscreener App
5.39
0.55%
-0.03
After Hours:
5.39
Curevac N V stock is traded at $5.39, with a volume of 1.07M.
It is down -0.55% in the last 24 hours and down -0.74% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.42
Open:
$5.4
24h Volume:
1.07M
Relative Volume:
0.88
Market Cap:
$1.21B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.8286
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-0.92%
1M Performance:
-0.74%
6M Performance:
+42.22%
1Y Performance:
+42.97%
1-Day Range:
$5.35
$5.415
1-Week Range:
$5.35
$5.47
52-Week Range:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.39 | 1.22B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
What makes CureVac N.V. stock price move sharplyTop Growth Ideas For 2025 - jammulinksnews.com
Short Covering May Lift CureVac N.V. in Near TermRisk Adjusted Technical Entry Plan Gains Followers - metal.it
CureVac N.V.Finanzen.net - Finanzen.net
Will CureVac N.V. stock benefit from AI tech trendsWatchlist for Smart Swing Trading Updated - metal.it
How volatile is CureVac N.V. stock compared to the marketIdentify winners with top-tier analysis - jammulinksnews.com
Traders Consider Averaging Down in CureVac N.V.Smart Investment Tips Gaining Popularity Among Analysts - metal.it
What are analysts’ price targets for CureVac N.V. in the next 12 monthsInvest confidently with professional market insights - jammulinksnews.com
How does CureVac N.V. generate profit in a changing economyTremendous wealth creation - jammulinksnews.com
Why is CureVac N.V. stock attracting strong analyst attentionMaximize returns with expert trading insights - jammulinksnews.com
Should I hold or sell CureVac N.V. stock in 2025Maximize returns with strategic trading plans - jammulinksnews.com
When is CureVac N.V. stock expected to show significant growthExceptional portfolio growth - jammulinksnews.com
What is the dividend policy of CureVac N.V. stockBuild a balanced portfolio for long-term success - jammulinksnews.com
What drives CureVac N.V. stock priceExplosive trading opportunities - PrintWeekIndia
Will CureVac N.V. stock benefit from interest rate changesFree Stock Market Real-Time Monitoring - jammulinksnews.com
Is CureVac N.V. a good long term investmentMarket-beating returns - Autocar Professional
DekaBank Deutsche Girozentrale Buys Shares of 1,941 CureVac (NASDAQ:CVAC) - 富途牛牛
What analysts say about CureVac N.V. stockExponential return rates - Autocar Professional
CureVac N.V. Stock Analysis and ForecastUnmatched profit potential - jammulinksnews.com
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - MSN
CureVac: Pipeline pruning’s nasty effect - MarketScreener
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):